Sarah Blagden
0000-0001-8783-3491
Organisation
5 papers found
Refreshing results…
A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer
A Phase Ib Open-Label, Dose-Escalation Study of NUC-1031 in Combination with Carboplatin for Recurrent Ovarian Cancer
Germline and somatic genetic variants in the p53 pathway interact to affect cancer risk, progression, and drug response
The Oxford Classic Links Epithelial-to-Mesenchymal Transition to Immunosuppression in Poor Prognosis Ovarian Cancers
Controversies around the function of LARP1
Missing publications? Search for publications with a matching author name.